

# UK Patent Application GB 2 246 569 A

(43) Date of publication 05.02.1992

(21) Application No 9013410.7

(22) Date of filing 16.06.1990

(71) Applicant  
The Charing Cross Sunley Research Centre

(Incorporated in the United Kingdom)

1 Lurgen Avenue, Hammersmith, London, W6 8LW,  
United Kingdom

(72) Inventors

Marc Poldman  
Patrick Gray  
Martin Turner  
Flonula Brennen

(74) Agent and/or Address for Service

J A Kemp & Co  
14 South Square, Gray's Inn, London, WC1R 5LX,  
United Kingdom

(61) INT CL<sup>4</sup>  
C07K 15/00, C12N 15/12 // (C12N 15/12 C12R 1:19  
1:866 1:91)

(62) UK CL (Edition K)  
C3H H87P H842 H850 H854 H858 H866  
C8Y Y126 Y320 Y402 Y408 Y419  
U1B S2411 S2410 S2418

(63) Documents cited  
EP 0433900 A1 EP 0418014 A1 EP 0393438 A2  
Embo. J., Vol.9, No. 16, 1990, pages 3269-3278.  
Science, Vol. 248, 26th May, 1990, pages 1019-1023.  
Cell, Vol. 61, April 20th, 1990, pages 351-358.

(68) Field of search  
UK CL (Edition K) C3H H87P  
INT CL C07K, C12H  
Online databases: WPI; DIALOG (BIOTECH)

## (54) Tumour necrosis factor - alpha binding protein

(57) A protein or polypeptide which has the amino acid sequence of the extracellular domain of human TNF- $\alpha$  receptor, and in particular polypeptides having the amino acid sequence (I):

L V P H L G D R E K R D S V C P Q Q K Y I H P Q N N S I C C T K C H K G T Y L N D C P Q Q D T D C R E C E S G S  
F T A S E N H L H H C L S C S K C A K E M G Q V E I S S C T V D R D T V C G C R K N Q Y R H Y W S E N L F Q C F N  
C S L C L N G T V H L S C O E K Q N T V C T C H A G F F L R E N E C V S C S N C K K S I E C T K I C I P O I, or a derivative thereof to which human TNF- $\alpha$  is capable of binding and whose amino acid sequence has a degree of homology of 80% or more with the sequence (I). The above amino acid sequence may be modified by removal of the first 11 aminoterminal residues and by extension at the carboxyl end with E N V K G T E D S G T T. The DNA sequence for polypeptide (I) is also given.

The protein is useful in the treatment of rheumatoid arthritis.

GB 2 246 569 A

At least one drawing originally filed was informal and the print reproduced here is taken from a later filed formal copy.

Fig. 1


1 ACCA GTATCTCT'A TGCCCCAGTC TCAACCTCA ACTGTCACCC CAAGGCACTT GGGACGGTCT GGAACGACCG  
75 AGTCCCCGAA AGGCCAGCA CTCGGCTGC CACACTCCCG TGAGGCCAAA TGGGGAGTC AGAGGCCATA CCTGTCTGGC

*Fig. 1 (cont.)*

225 K P L A P N P S F S P T P G F T P T L S F S P V  
 948 AAG CCC CTC GCG CCC AAC CCA AGC TTC AGT CCC ACT CCA GCC TTC AGT CCC AGT CCC GTC AGT CCC GTC  
 249 P S S T P T S S S T Y T P G D C P N P A A P R R  
 1020 CCC AGT TCC ACC TTC ACC TCC AGC  
 260. 724  
 273 E V A P P Y Q C A D P - L A T A L A S D P I P N  
 1052 GAG GTC GCA CCA CCC TAT CAG CGG GCT GAC CCC ATC CTC GCA AGC GCC CTC GCA CCC ATC CCC AAC  
 287 P L Q K W E D S A H K P Q S L D T D D P A T L Y  
 1164 CCC CTT CAG AAG TGG GAG GAC AGT GCC CAC AAG CCA CAG AGC CTA GAC ACT GAT GAC CCC GCG ACG CTG TAC 2/5  
 321 A V N V E N V P L R T L E ? V R R L C L S D H E  
 1236 GCC GTC GTC GAG AAC GTC CCC CCG TGG CGC TGG AAG GAA TTC GTC GTC CGC CGC CTA CGG CTG AGC GAC CAC GAG  
 345 I D R L E L Q N G R C L R E A Q V S M L A T N R  
 1308 ATC GAT CGC CTC GAG CTG CAG CGA AAC GGC CGC TGG CGC CGC GAG GCG GAA TAC AGC ATG CTC GCC AGC TGG AGG  
 369 R R T P R R E A T L E : L G R V L R M D L L C  
 1180 CGG CGC ACC CGG CGG GAG CCC ACC CTC GAG CTC GCA CGA CCC CTC CGC GAC ATG GAC CTG CTG CGC  
 1391 C L E D I B E A L C G P A L P P A S L L R  
 1452 TGC CTC GAG GAC ATC GAG GAG CGG CTT TGC EGC CCC GCG CTC CGC CCC AGT CTC CTC AGA TGA  
 1521 GGCTGGCCCC TGCGCGAGC TCTAAGGCC AGC TCTAAGGCC AGC TCTAAGGCC AGC TCTAAGGCC AGC TCTAAGGCC  
 1601 CTGCAAGGGCC AGCAGGAGC TAGCAGGCC CTACTGGTG CTAAACCCCTC GATGTACATA CCTTTCCTCA GCTTTCCTCA  
 1681 CGCGCGGAC AGTCAGGCT CTGCGAGGCT AGAGAGGTC GCGCTGGCT CAAGAGGCTG AGCTGGCTG TTGCGAGGAT  
 1761 GAGGGACGCT ATGCTCATG CCGCTTTCG GTGTCCTCAC CAGCAAGGCT GCTCGGGCC CCCTGGGGCC  
 1841 TTTTCACAG TGCATAAGCA GTTGTGTTT GTTGTGTTT TGTATCATGT TACACTAATA  
 1921 GAAACTGGCC ACTCTGGCC CCTCTGGCC GACAAGGAC ATAGCAGGT GAACGTGCTT AAGGAGGG OGAGGACCGA  
 2001 ACAATGGCCC CTCAGCTGG AGCTGGGAC TTTCGACAT AGACTTAAT TCTGAAGTTA AG

3/5


Fig. 2.



Northern blot (lanes 1-3) of 10 µg of oligo-dT selected RNA from human 293 cells (fibroblast cell line), placenta and spleen hybridised with the TNF receptor cDNA (SmaI-EcoRI fragment). The Southern blot (lanes 4-6) was hybridised with the same probe. Human genomic DNA (5 µg per lane) was digested with PstI (lane 4), Hind III (lane 5) and EcoRI (lane 6)


4/5

Fig. 3.



5/5

Fig. 4.



Effects of soluble TNF-R on TNF binding and biological activity.  
Panel A shows the effects of supernatants from Cos-7 cells transfected with a cDNA encoding a soluble form of the TNF receptor (pTNFRecd, closed circles) or mock transfected (open circles) on  $^{125}\text{I}$ -TNF binding to U937 cells. Panel B shows the effects of these supernatants on TNF mediated killing of WEHI 164 (clone 13) line. Assays were performed as described in Materials and Methods.

POLYPEPTIDE AND ITS USE

The present invention relates to recombinant proteins and their use.

Tumour necrosis factor- $\alpha$  (TNF $\alpha$ ) is a potent cytokine which elicits a broad spectrum of biological responses. TNF $\alpha$  causes the cytolysis or cytostasis of many tumour cell lines *in vitro*, induces the haemorrhagic necrosis of transplanted tumours in mice, enhances the phagocytosis and cytotoxicity of polymorphonuclear neutrophils, and modulates the expression of many proteins, including lipoprotein lipase, class I antigens of the major histocompatibility complex, and cytokines such as interleukin 1 and interleukin 6. TNF $\alpha$  appears to be necessary for a normal immune response, but large quantities produce dramatic pathogenic effects. TNF $\alpha$  has been termed "cachectin" since it is the predominant factor responsible for the wasting syndrome (cachexia) associated with neoplastic disease and parasitemia. TNF is also a major contributor to toxicity in gram-negative sepsis, since antibodies against TNF can protect infected animals.

The many activities of TNF $\alpha$  are mediated by binding to a cell surface receptor. Radioligand binding studies have confirmed the presence of TNF receptors on a wide variety of cell types. Although these receptors are expressed in limited numbers (1,000 - 10,000 receptors/cell), they bind TNF $\alpha$  with high affinity ( $K_a = 10^9 M^{-1}$  at 4°C). The TNF receptor has been characterised as a 65,000-80,000 dalton glycoprotein which binds both TNF $\alpha$  and the structurally related lymphotoxin (TNF $\beta$ ). Lymphotoxin has similar, if not identical, biological activities to TNF $\alpha$ , presumably because both are recognized by the same receptor. Recently, several laboratories have detected heterogeneity in TNF receptor preparations, and have proposed that at least two distinct cell surface molecules bind TNF $\alpha$ . In addition, both of these receptors appear to be released

from cells in soluble form, as TNF binding proteins of 30,000 daltons have been isolated from both urine and serum (1-3). This soluble extracellular domain retains the capacity to bind ligand with high affinity.

- 5 We have now expressed a polypeptide which corresponds to the extracellular domain of a human TNF $\alpha$  receptor. Further, this polypeptide is secreted as a soluble protein and is capable of binding human TNF $\alpha$ . The polypeptide can therefore be used in the treatment of disorders where TNF $\alpha$  10 has a significant causative role.

Accordingly, the present invention provides a polypeptide having the amino acid sequence (I):

L V P H L G D R E K R D S V C P Q G K Y  
I H P Q N N S I C C T K C H K G T Y L Y  
15 N D C P G P G Q D T D C R E C E S G S F  
T A S E N H L R H C L S C S K C R K E M  
C Q V E I S S C T V D R D T V C G C R K  
N Q Y R H Y W S E N L F Q C F N C S L C  
L N G T V H L S C Q E K Q N T V C T C H  
20 A G F F L R E N E C V S C S N C K K S L  
E C T K L C L P Q I

or a derivative thereof to which human TNF $\alpha$  is capable of binding and whose amino acid sequence has a degree of homology of 90% or more with the sequence (I).

- 25 The invention also provides a DNA sequence which encodes this polypeptide. The DNA sequence may be:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT  
CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT  
ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC  
30 CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC  
ACC CCT TCA GAA AAC CAC CTC AGA CAC TCC CTC AGC TGC TCC AAA  
TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG  
GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT  
TAT TCC ACT CAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC  
35 CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC

GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAC TCT  
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG  
TGC CTA CCC CAG ATT

The invention further provides a vector which  
5 incorporates a DNA sequence of the invention and which is  
capable, when provided in a transformed host, of expressing  
the polypeptide of the invention encoded by the DNA  
sequence. A host transformed with such a vector forms part  
of the present invention too.

10 In the accompanying drawings:

Figure 1 shows the nucleotide sequence of the human TNF $\alpha$   
cDNA and encoded amino acid sequence. The predicted signal  
sequence residues are numbered -40 to -1. The  
transmembrane domain is boxed and potential N-linked  
15 glycosylation sites are overlined. The sequence homologous  
with the designed oligonucleotide probe is found at  
nucleotide positions 477-533.

Figure 2 is a Northern blot (lanes 1-3) of 10 $\mu$ g of  
oligo-dT selected RNA from human 293 cells (fibroblast cell  
20 line) (lane 1), placenta (lane 2) and spleen (lane 3)  
hybridised with the TNF receptor cDNA (SmaI-EcoRI  
fragment). The Southern blot (lanes 4-6) was hybridized  
with the same probe. Human genomic DNA (5  $\mu$ g per lane) was  
digested with PstI (lane 4). Hind III (lane 5) and EcoRI  
25 (lane 6).

Figure 3 shows the binding characteristics of  
recombinant human TNF receptor expressed in COS-7 cells.  
The direct binding of recombinant  $^{125}$ I-TNF $\alpha$  to COS-7 cells  
transfected with pRTNFR is presented in panel A. The inset  
30 contains Scatchard analysis derived from this data. As  
shown in panel B, monolayers of Cos-7 cells transfected  
with TNF-R cDNA were incubated with 1nM  $^{125}$ I-TNF in the  
presence of various concentrations of unlabelled TNF or LT.

Figure 4 shows the effects of soluble TNF-R on TNF  
35 binding and biological activity. Panel A shows the effects

of supernatants from COS-7 cells transfected with a cDNA encoding a soluble form of the TNF receptor (pTNFRecd, closed circles) or mock transfected (open circles) on  $^{125}\text{I}$ -TNF binding to U937 cells. Panel B shows the effects 5 of these supernatants on TNF mediated killing of WEHI 164 (clone 13) line. Assays were performed as described in Materials and Methods.

In order to obtain a derivative of the polypeptide of the invention, the amino acid sequence shown above may be 10 modified by one or more amino acid substitutions, insertions and/or deletions and/or by an extension at either or each end. A polypeptide composed of such a modified sequence must of course still be capable of binding human TNF $\alpha$ . Typically a modified polypeptide has a 15 binding affinity for human TNF $\alpha$  of  $10^7\text{M}^{-1}$  or greater, for example  $10^8\text{M}^{-1}$  or greater. The affinity may be from  $10^7$  to  $10^{10}\text{M}^{-1}$ , for example from  $10^8$  to  $10^9\text{M}^{-1}$ . When the unmodified amino acid sequence shown above is modified 20 there is a degree of homology of 90% or more or 95% or more between the modified and unmodified sequence.

For example, one or more amino acid residues of the sequence above may be substituted or deleted or one or more additional amino acid residues may be inserted; provided the physicochemical character of the original sequence is 25 preserved, i.e. in terms of charge density, hydrophobicity/hydrophilicity, size and configuration. Candidate substitutions are, based on the one-letter code (Eur. J.

Biochem. 128, 9-37, 1904):

A for G and vice versa,

30 V by A, I or G;

K by R;

S by T and vice versa;

E for D and vice versa; and

Q by N and vice versa.

Up to 15 residues may be deleted from the N-terminal of the polypeptide, for example up to 11 residues or up to 5 residues. As far as extensions are concerned, a short sequence or up to 50 amino acid residues may be provided at 5 either or each terminal. The sequence may have up to 30, for example up to 20 or up to 10, amino acid residues. Up to 12 residues, for example up to 9 residues or up to 5 residues, may be added to the C-terminal of the polypeptide in the order E N V K G T E D S G T T.

10 Alternatively, a much longer extension may be present. Longer amino acid sequences may be fused to either or each end. A chimaeric protein may therefore be provided in which the or each extension is a heterologous amino acid sequence, i.e. a sequence not naturally linked to the amino 15 acid sequence above. Such a chimaeric protein may therefore combine the ability to bind specifically to human TNF $\alpha$  with another functionality.

The polypeptides are prepared by recombinant DNA technology. The preparation of the polypeptides therefore 20 depends upon the provision of a DNA sequence encoding the polypeptide. DNA comprising the nucleotide sequence shown above may be obtained by probing a human placenta cDNA library, for example a  $\lambda$ gt11 library. Such a library is available from Clontech. A suitable probe is:

25 AAG GAG ATG GGC CAG GTT GAG ATC TCT TCT ACT GTT GAC AAT GAC  
ACT GTG TGT GGC

A modified form of the nucleotide sequence shown above, a polypeptide having the amino acid sequence shown above or a derivative polypeptide, may be obtained by use of any 30 appropriate technique, including restriction with an endonuclease, insertion of linkers, use of an exonuclease and/or a polymerase and site-directed mutagenesis. Whether a modified DNA sequence encodes a polypeptide of the invention can be readily ascertained. The polypeptide 35 encoded by the sequence can be expressed in a suitable host

and tested for its ability to bind specifically human TNF<sub>a</sub>.

For expression of a polypeptide of the invention, an expression vector is constructed. An expression vector is prepared which comprises a DNA sequence encoding a

- 5 polypeptide of the invention and which is capable of expressing the polypeptide when provided in a suitable host. Appropriate transcriptional and translational control elements are provided, including a promoter for the DNA sequence, a transcriptional termination site, and
- 10 translational start and stop codons. The DNA sequence is provided in the correct frame such as to enable expression of the polypeptide to occur in a host compatible with the vector.

The expression vector is then provided in an appropriate host. Cells harbouring the vector are grown so as to enable expression to occur. The vector may be a plasmid or a viral vector. Any appropriate host-vector system may be employed.

The transformed host may be a prokaryotic or eukaryotic host. A bacterial or yeast host may be employed, for example *E. coli* or *S. cerevisiae*. Insect cells can alternatively be used, in which case a baculovirus expression system may be appropriate. As a further alternative, cells of a mammalian cell line, such as Chinese Hamster Ovary (CHO) Cells may be transformed. A polypeptide glycosylated at one, two or three of the sites shown in Figure 1 can be obtained by suitable choice of the host cell culture.

The polypeptide of the invention can be isolated and purified. The polypeptide is soluble. It can be employed in the regulation of TNF-mediated responses by binding and sequestering the cytokine. The polypeptide can therefore be used therapeutically to treat disorders such as cachexia, sepsis and autoimmune diseases such as rheumatoid arthritis.

For this purpose, a polypeptide of the present invention may be formulated in a pharmaceutical composition. The pharmaceutical composition also comprises a pharmaceutically acceptable carrier or diluent.

5      The polypeptide of the invention may be administered to a patient by any convenient route. The choice of whether an oral route or a parenteral route, such as subcutaneous, intravenous or intramuscular administration, is adopted; of the dose; and of the frequency of administration depends  
10 upon a variety of factors. These factors include the purpose of the administration, the age and weight of the patient being treated and the condition of the patient. Typically, however, the polypeptide is administered in an amount of from 1 to 1000 µg per dose, more preferably from  
15 10 to 100 µg per dose, for each route of administration.

The invention further provides a protein which has the amino acid sequence of the extracellular domain of a human TNF $\alpha$  receptor, or a derivative thereof to which human TNF $\alpha$  is capable of binding, for use in a method of treatment of  
20 the human or animal body by therapy; especially for use in the treatment of an autoimmune disease in which TNF $\alpha$  plays a significant causative role, such as rheumatoid arthritis.

The extracellular domain of a TNF $\alpha$  receptor, or a derivative thereof capable of binding human TNF $\alpha$ , may  
25 therefore be used to treat rheumatoid arthritis. The extracellular domain, or a derivative thereof, of either of the two structurally distinct human TNF receptors may be used. A suitable polypeptide has the amino acid sequence (II):

30 D S V C P Q G K Y I H P Q N N S I C C T  
K C H K G T Y L Y N D C P C P C Q D T D  
C R E C E S G S F T A S E N H L R H C L  
S C S K C R K E M G Q V E I S S C T V D  
R D T V C G C R K N Q Y R H Y W S E N L  
35 F Q C F N C S L C L N G T V H L S C Q E

K Q N T V C T C H A G F F L R E N E C V  
S C S N C K K S L E C T K L C L P Q I E  
N V K G T E D S G T T

or a derivative thereof to which human TNF<sub>a</sub> is capable of  
5 binding.

The amino acid sequence of an extracellular domain such as sequence (II) shown above may be modified by one or more amino acid substitutions, insertions and/or deletions and/or by an extension at either or each end. A 10 polypeptide composed of such a modified sequence must of course still be capable of binding human TNF<sub>a</sub>. Typically a modified polypeptide has a binding affinity for human TNF<sub>a</sub> of  $10^7 M^{-1}$  or greater, for example  $10^8 M^{-1}$  or greater. The affinity may be from  $10^7$  to  $10^{10} M^{-1}$ , for example from  $10^8$  15 to  $10^9 M^{-1}$ . When the unmodified amino acid sequence shown above is modified there is a degree of homology of 90% or more or 95% or more between the modified and unmodified sequence.

For example, one or more amino acid residues of the 20 sequence above may be substituted or deleted or one or more additional amino acid residues may be inserted; provided the physicochemical character of the original sequence is preserved, i.e. in terms of charge density, hydrophobicity/hydrophilicity, size and configuration. Candidate 25 substitutions are, based on the one-letter code (Eur. J. Biochem. 138, 9-37, 1984):

A for G and vice versa,

V by A, L or G;

K by R;

30 S by T and vice versa;

E for D and vice versa; and

Q by N and vice versa.

Up to 15 residues may be added to the N-terminal of the 35 polypeptide, for example up to 11 residues or up to 5 residues. As far as extensions are concerned, a short sequence of up to 50 amino acid residues may be provided at

either or each terminal. The sequence may have up to 30, for example up to 20 or up to 10, amino acid residues. Up to 12 residues, for example up to 9 residues or up to 5 residues, may be deleted from the C-terminal of the 5 polypeptide.

For this purpose, a polypeptide may be formulated in a pharmaceutical composition. The pharmaceutical composition also comprises a pharmaceutically acceptable carrier or diluent. The polypeptide is typically a recombinant 10 polypeptide in pure form.

The polypeptide may be administered to a patient by any convenient route. The choice of whether an oral route or a parenteral route, such as subcutaneous, intravenous or intramuscular administration, is adopted; of the dose; and 15 of the frequency of administration depends upon a variety of factors. These factors include the purpose of the administration, the age and weight of the patient being treated and the condition of the patient. Typically, however, the polypeptide is administered in an amount of 20 from 1 to 1000 µg per dose, more preferably from 10 to 100 µg per dose, for each route of administration.

The following Example illustrates the invention.

#### EXAMPLE

##### 1. Materials and Methods

###### 25      Reagents

Recombinant human TNF $\alpha$  and TNF $\beta$  were supplied as highly purified proteins derived from *E. coli*. The specific activities of these preparations were approximately 10<sup>7</sup> units/mg, as measured in the murine L929 cell cytotoxicity 30 assay. The synthetic oligonucleotides were prepared by Oswel DNA Service (University of Edinburgh).

###### Isolation of TNF receptor cDNA clones

The sequence of a peptide fragment (E M G Q V E I S S T

V D R D T V C G) of the TNF binding protein was used to design a synthetic oligonucleotide probe (5' AAG GAG ATG GGC CAG GTT GAG ATC TCT TCT ACT GTT GAC AAT GAC ACT GTG TGT CCC-3'). The 57-mer DNA probe was labelled with  $^{32}\text{P}$  and T4 5 polynucleotide kinase (New England Biolab, Beverly, MA) and used to screen a placenta cDNA library in  $\lambda$ gt10 (4,5). Approximately 800,000 phage were transferred to nitrocellulose filters and screened at reduced stringency (6). Filters were incubated for 2 hours at 42°C in 0.05M 10 sodium phosphate, pH 6.5, 20% formamide, 0.75 M sodium chloride, 0.075 M sodium citrate, 1% polyvinyl pyrrolidone (Sigma, St Louis, MO), 1% Ficoll, 1% bovine serum albumin (Sigma), and 50 ng/ml sonicated salmon sperm DNA (Sigma). The radiolabelled probe was then added to the filters ( $10^8$  15 cpm/ml final concentration) which were hybridized for 16 hours. Filters were washed extensively in 0.06M sodium chloride, 0.006M sodium citrate, 1% SDS at 37°C and positive clones were identified by autoradiography. Ten hybridizing clones were plaque purified (4) and cDNA insert 20 size was determined by polyacrylamide gel electrophoresis of EcoRI digested phage DNA. The inserts of two cDNA clones were sequenced using the dideoxy chain termination technique (7).

Southern and Northern blot analysis

25 DNA was isolated from human lymphocytes by the method of Blin and Stafford (8) and used for Southern blot analysis (9). DNA was digested with restriction endonucleases (New England Biolabs), fractionated on a 1% agarose gel, and transferred to nitrocellulose. Hybridization and washing 30 were conducted under stringent conditions (5) using a  $^{32}\text{P}$ -labelled preparation of a 600 bp fragment of the TNF receptor cDNA. Northern blot analysis was performed (10) on oligo-dT selected RNA isolated from human placenta, spleen (generously provided by the Cooperative Human Tissue 35 Network, Birmingham, AL) and a fibroblast cell line (293

cells). Following electrophoresis on a formaldehyde 1.2% agarose gel, the RNA was transferred to nitrocellulose and hybridized with the TNF receptor DNA probe under stringent conditions.

5       Mammalian cell expression of the human TNF receptor and derivatives

The coding region of the majority of the human TNF receptor was isolated as an EcoRI fragment and cloned into a mammalian cell expression vector (11), resulting in 10 plasmid prTNFR. The EcoRI fragment encodes 374 amino acids of the TNF receptor; the 81 carboxyl terminal residues of the cytoplasmic domain are therefore missing from this plasmid construction. A derivative of the TNF receptor was produced by engineering a termination codon just prior to 15 the transmembrane domain. The polymerase chain reaction (PCR) technique (12) was used to generate a 300 bp restriction fragment containing a BgIII site at the 5' end and a HindIII site preceded by a TAG stop codon at the 3' end. The PCR primers were 5'CCTGCTCCAAATGCCGAAG and 20 5'AGTTCAAGCTTTACAGTGCCCTAACATTCTAA. The PCR product was gel purified and cloned into the TNF receptor expression plasmid (described above) digested with BgIII and HindIII. DNA sequencing confirmed that the resulting plasmid (pTNFRecd) contained the designed DNA sequence.

25       The TNF receptor expression plasmids were transfected into monkey COS-7 cells using Lipofectin (Gibco BRL, Bethesda, MD) according to the manufacturer's instructions. Cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum.

30       Analysis of recombinant TNF receptor derivatives

TNF $\alpha$  was radioiodinated with the Iodogen method (Pierce) according to the manufacturer's directions. The specific activity of the  $^{125}\text{I}$ -TNF $\alpha$  was 10-30  $\mu\text{Ci}$   $\mu\text{g}$ . COS cells

- transfected with the TNF receptor cDNA (pTNFR, 1300 bp EcoRI fragment) were incubated for 24 hours and then seeded into six well tissue culture plates (Nunc) at  $4.5 \times 10^8$  cells per well. The cells were incubated for a further 48 hours and then receptor expression was quantitated by radioligand binding for 3 hours at 4°C. Non-specific binding of  $^{125}\text{I}$ -TNFa was determined in the presence of a 1,000 fold molar excess of unlabelled TNFa. Binding data was analysed by the method of Scatchard (13).
- The TNF receptor derivative was analysed for inhibition of  $^{125}\text{I}$ -TNFa binding to the natural receptor on human U937 cells. Culture supernatant was harvested 72 hours after COS cells were transfected with pTNFRecd. U937 cells ( $2 \times 10^8$  cells in 200  $\mu\text{l}$ ) were incubated with 1nM  $^{125}\text{I}$ -TNFa and dilutions of COS cell media for 2 hours at 4°C. Cells were then centrifuged through 20% sucrose to remove unbound TNFa. Non specific binding was determined in the presence of 1 $\mu\text{M}$  unlabelled TNFa.
- The TNF receptor derivative was also analyzed for inhibition of TNFa cytotoxic effects in vitro. The cytotoxicity assay was performed as described on the TNF sensitive cell line WEHI 164 clone 13 (14). Serial dilutions of supernatants from COS cells transfected with pTNFRecd or mock transfected controls were incubated with a constant amount of TNFa (1 ng/ml) for 1 hour at 27°C before addition to the assay.

## 2. RESULTS

Isolation and characterization of the TNF receptor cDNA  
A partial amino acid sequence of the TNF binding protein was used to design a synthetic oligonucleotide probe. The radiolabelled probe was used to screen a human placenta cDNA library in  $\lambda$ gt10 and ten hybridizing phage were isolated. The nucleotide and deduced amino acid sequences of the longest cDNA clone are depicted in Figure 1. The

third potential ATG initiation codon occurs at position 156 of the nucleotide sequence; the first two ATG codons are closely followed by termination codons, and the third ATG is preceded by the best translation initiation consensus 5 nucleotides (15). The cDNA encodes an open reading frame of 1365 bases which codes for a polypeptide of 455 residues. Both of the peptide sequences determined by amino acid sequencing were identified in the encoded cDNA (17 of 19 and 18 of 19 matching residues). The amino 10 terminal end identified for the TNF binding protein corresponds to the cDNA encoded sequence beginning at residue 41. The first 35 amino acids are generally quite hydrophobic and probably represent a signal sequence. Residues 36-40 are highly charged (DREK) and such a 15 sequence is not typically found in secretory signal sequences (16); perhaps the natural receptor is processed by proteolysis after residue 40 which contains a dibasic cleavage site (KR). Hydropathy analysis of the protein sequence predicts a single transmembrane domain of 23 amino 20 acids. This hydrophobic sequence divides the protein into an extracellular domain of 171 residues and a cytoplasmic domain of 221 residues. The amino acid composition determined for the TNF binding protein (2) corresponds well with the predicted composition of the extracellular domain 25 encoded by the cDNA (results not shown). The discrepancy between the predicted receptor size (40,000 daltons) and the size determined by SDS-polyacrylamide gel electrophoresis (65,000 daltons, 17-19) is probably due to glycosylation; there are four potential N-linked 30 glycosylation sites in the sequence, three of which are in the extracellular domain. The sequence contains a large number (16) of cysteine residues, 24 of which are in the extracellular domain. The arrangement of these cysteine is similar to that of several other cell surface proteins, 35 suggesting that the TNF receptor is structurally related to

a family of receptors.

A Northern blot analysis is presented in Figure 2. The  $^{32}\text{P}$ -labelled cDNA hybridized to a single predominant band of oligo-dT selected RNA from human placenta or spleen. A minor larger transcript was also observed in RNA from a fibroblast cell line. The size of the hybridizing species is 2400 bases, in good agreement with the size of isolated cDNA. Also shown in Figure 2 is a Southern blot of human genomic DNA hybridized with a 600 bp probe from the cDNA. In each of the three different restriction digests, only a single hybridized signal was observed. Thus the TNF receptor that we have isolated appears to be encoded by a single gene.

15 Expression of recombinant TNF receptor sequences in mammalian cells

To confirm that the cDNA shown in Figure 1 indeed encodes the TNF receptor, the cDNA was engineered for expression in mammalian cells. The cDNA contains an EcoRI site at position 1270 of Figure 1. The receptor coding sequence was isolated as a 1300 bp EcoRI-fragment (containing all but the last 81 codons of the cytoplasmic domain) and inserted into a mammalian cell expression vector containing a cytomegalovirus promoter and SV40 transcription termination sequences (11). The resulting plasmid was transfected into COS cells which were analyzed for TNF receptor expression after three days. As shown in Figure 3, the transfected cells specifically bound radioiodinated TNF $\alpha$  in a saturable and dose dependent fashion. The population of COS cells expressed approximately  $1 \times 10^8$  receptors per cell. The measured binding affinity of recombinant receptors was  $2.5 \times 10^9 \text{ M}^{-1}$  at 4°C which is in close agreement with natural receptor on human cells (18,19). The binding of  $^{125}\text{I}$ -TNF $\alpha$ (1 nM) to these cells could be inhibited by the addition of

unlabelled TNF $\alpha$  or lymphotoxin (Figure 3b). COS cells transfected with just the expression vector did not significantly bind  $^{125}\text{I}$ -TNF $\alpha$  (less than 2% of the binding seen with the cDNA transfection).

5      The extracellular domain of the TNF receptor is naturally shed from cells (1-3). To produce a similar recombinant derivative, a stop codon preceding the transmembrane domain was engineered into the cDNA by PCR mutagenesis. The modified DNA was inserted into the  
10 expression plasmid and subsequently transfected into COS cells. After three days, the COS cell media was tested for inhibition of TNF $\alpha$  binding to human U937 cells. As shown in Figure 4a, the transfected cell media inhibited up to 70% of the binding of TNF $\alpha$ . The recombinant TNF receptor  
15 derivative was next tested for inhibition of TNF $\alpha$  biological activity. A sensitive bioassay for TNF $\alpha$  is a measurement of cytolysis of mouse WEHI 164 (clone 13) cells. The transfected cell media inhibited 60% of TNF $\alpha$  cytotoxicity on this cell line (Figure 4b). Media from  
20 mock transfected COS cells did not inhibit TNF $\alpha$  induced cytotoxicity or binding. These experiments demonstrate that the recombinant extracellular domain of the TNF receptor is capable of binding TNF and inhibiting its biological activity.

REFERENCES

1. Englemann, H., Novick, D. and Wallach, D. (1990) J. Biol. Chem. 265, 1531-1536.
2. Olsson, I., Lantz, M., Nilsson, E., Peatre, C.,  
5 Thysell, H., Grubb, A. and Adolf, G. (1989) Eur. J. Haematol 42, 270-276.
3. Sackinger, P., Isaaz, S. and Dayer, J-M (1989) J. Biol. Chem. 264, 11966-11973.
4. Maniatis, T., Hardison, R.C., Lacy, E., Lauer, J.,  
10 O'Connell, C., Quon, D., Sim, G.K. and Efstratiadis, A. (1978) Cell 15, 687-701.
5. Lawn, R.M., Fritsch, E.F., Parker, R.C., Blake, G & Maniatis, T. (1978) Cell 15, 1157-1174.
6. Gray, P.W., Leong, S.R., Fennie, E., Farrar, M.A.,  
15 Pingel, J.T. and Schreiber, R.D. (1989) Proc. Natl. Acad. Sci USA 86, 0497-0501.
7. Smith, A.J.H., (1980) Meth. Enzym. 65 560-580.
8. Blin, N. & Stanford, D.W. (1976) Nucl. Acids Res. 3, 2303-2398.
- 20 9. Southern, E.M. (1975) J. Molec. Biol. 98, 503-517.
10. Dobner, P.R., Kawasaki, E.S., Yu, L.Y. and Bancroft, F.C. (1981) Proc. Natl. Acad. Sci. USA. 78, 2230-2234.
11. Eaton, D.L., Wood, W.I., Eaton, D., Hess, P.E.,  
25 Hollinghead, P., Wion, K., Mather, J., Lawn, R.M., Vahar, G.A. and Gorman, C. (1986) Biochemistry 25: 8343-8347.
12. Scharf, S.J., Horn, G.T., Erlich, H.A. (1986) Science 233, 1076-1079.
13. Scatchard, G. (1949) Nature 237, 680-685.
- 30 14. Espevik, T. & Nissen-Meyer, J. (1986) J. Immunol. Meths. 95, 99-105.
15. Kozak, M. (1989) J. Cell. Biol. 108, 229-241.
16. von Heijne, G. (1988) Nucl. Acids. Res. 14, 4683-4690.
17. Creasy, A.A., Yamamoto, R. & Vitt, C.R. (1987) Proc.  
35 Natl. Acad. Sci. USA. 84, 3293-3297.

- 17 -

18. Stauber, G.B., Alyar,R.A. & Aggarwal, B.B. (1988) J. Biol. Chem. 263, 19098-19104.
19. Scheurich, P., Ucer, U., Kronke, M. and Pfizenmaier, K. (1986) Int. J. Cancer, 38, 127-133.

**CLAIMS**

1. A polypeptide having the amino acid sequence:

L V P H L G D R E K R D S V C P Q G K Y  
I H D Q N N S I C C T K C H K G T Y L Y  
5 N D C P G P G Q D T D C R E C E S G S F  
T A S E N H L R H C L S C S K C R K D M  
G Q V E I S S C T V D R D T V C G C R K  
N Q Y R H Y W S E N L F Q C F N C S L C  
L N G T V H L S C Q E K Q N T V C T C H  
10 A G F F L R E N E C V S C S N C K K S L  
E C T X L C L P Q I

or a derivative thereof to which human TNF $\alpha$  is capable of binding and whose amino acid sequence has a degree of homology of 90% more with the sequence (I).

15 2. A DNA sequence which encodes a polypeptide as defined in claim 1.

3. A DNA sequence according to claim 2, which is:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT  
CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT  
20 ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA CCC  
CCG CGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC  
ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA  
TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TCC ACA GTG  
GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT  
25 TAT TCG ACT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC  
CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC  
GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT  
CTC TCC TGT ACT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG  
TGC CTA CCC CAG ATT

30 4. A DNA sequence according to claim 3, which further comprises a 5' sequence which encodes a signal amino acid sequence.

35 5. A vector which incorporates a DNA sequence as claimed in any one of claims 2 to 4 and which is capable, when provided in a suitable host, of expressing the said

polypeptide.

6. A vector according to claim 5, which is a plasmid.

7. A host transformed with a vector as claimed in  
3 claim 5 or 6.

8. A host according to claim 7, which is a mammalian cell line.

9. A process for the preparation of a polypeptide as defined in claim 1, which process comprises culturing a 10 transformed host as claimed in claim 7 or 8 under such conditions that the said polypeptide is expressed.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as an active principle, a polypeptide as claimed in claim 1.

11. A protein which has the amino acid sequence of the extracellular domain of a human TNF $\alpha$  receptor, or a derivative thereof to which human TNF $\alpha$  is capable of binding, for use in a method of treatment of the human or animal body by therapy.

12. A protein according to claim 11, for use in the treatment of rheumatoid arthritis.

13. A protein according to claim 11 or 12, which is a polypeptide as defined in claim 1.